Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19 : A Randomized Clinical Trial
IMPORTANCE: Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective: To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non-critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS: Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was organ support-free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS: On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support-free days among critically ill patients was 10 (-1 to 16) in the ACE inhibitor group (n = 231), 8 (-1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support-free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE: In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.
| Errataetall: |
CommentIn: JAMA. 2023 Apr 11;329(14):1155-1156. - PMID 37039803 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:329 |
|---|---|
| Enthalten in: |
JAMA - 329(2023), 14 vom: 11. Apr., Seite 1183-1196 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Writing Committee for the REMAP-CAP Investigators [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 17.04.2023 Date Revised 19.04.2024 published: Print ClinicalTrials.gov: NCT02735707 CommentIn: JAMA. 2023 Apr 11;329(14):1155-1156. - PMID 37039803 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jama.2023.4480 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355443430 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355443430 | ||
| 003 | DE-627 | ||
| 005 | 20240419232029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2023.4480 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM355443430 | ||
| 035 | |a (NLM)37039790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Writing Committee for the REMAP-CAP Investigators |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19 |b A Randomized Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2023 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02735707 | ||
| 500 | |a CommentIn: JAMA. 2023 Apr 11;329(14):1155-1156. - PMID 37039803 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19 | ||
| 520 | |a Objective: To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19 | ||
| 520 | |a DESIGN, SETTING, AND PARTICIPANTS: In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non-critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022) | ||
| 520 | |a INTERVENTIONS: Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days | ||
| 520 | |a MAIN OUTCOMES AND MEASURES: The primary outcome was organ support-free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes | ||
| 520 | |a RESULTS: On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support-free days among critically ill patients was 10 (-1 to 16) in the ACE inhibitor group (n = 231), 8 (-1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support-free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively) | ||
| 520 | |a CONCLUSIONS AND RELEVANCE: In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Receptors, Chemokine |2 NLM | |
| 700 | 1 | |a Lawler, Patrick R |e verfasserin |4 aut | |
| 700 | 1 | |a Derde, Lennie P G |e verfasserin |4 aut | |
| 700 | 1 | |a van de Veerdonk, Frank L |e verfasserin |4 aut | |
| 700 | 1 | |a McVerry, Bryan J |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Lindsay R |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzi, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a van Kimmenade, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Gommans, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Vaduganathan, Muthiah |e verfasserin |4 aut | |
| 700 | 1 | |a Leaf, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Baron, Rebecca M |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Edy Y |e verfasserin |4 aut | |
| 700 | 1 | |a Frankfurter, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Epelman, Slava |e verfasserin |4 aut | |
| 700 | 1 | |a Kwan, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Grieve, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neill, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Sadique, Zia |e verfasserin |4 aut | |
| 700 | 1 | |a Puskarich, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Higgins, Alisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Mouncey, Paul R |e verfasserin |4 aut | |
| 700 | 1 | |a Rowan, Kathryn M |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Beidh, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Annane, Djillali |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M |e verfasserin |4 aut | |
| 700 | 1 | |a Au, Carly |e verfasserin |4 aut | |
| 700 | 1 | |a Beane, Abi |e verfasserin |4 aut | |
| 700 | 1 | |a van Bentum-Puijk, Wilma |e verfasserin |4 aut | |
| 700 | 1 | |a Bonten, Marc J M |e verfasserin |4 aut | |
| 700 | 1 | |a Bradbury, Charlotte A |e verfasserin |4 aut | |
| 700 | 1 | |a Brunkhorst, Frank M |e verfasserin |4 aut | |
| 700 | 1 | |a Burrell, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Buzgau, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Buxton, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Cecconi, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Allen C |e verfasserin |4 aut | |
| 700 | 1 | |a Cove, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Detry, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Estcourt, Lise J |e verfasserin |4 aut | |
| 700 | 1 | |a Ezekowitz, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Gattas, David |e verfasserin |4 aut | |
| 700 | 1 | |a Godoy, Lucas C |e verfasserin |4 aut | |
| 700 | 1 | |a Goossens, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Haniffa, Rashan |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Hills, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Horvat, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Ichihara, Nao |e verfasserin |4 aut | |
| 700 | 1 | |a Lamontagne, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Linstrum, Kelsey M |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a McGlothlin, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a McGuinness, Shay P |e verfasserin |4 aut | |
| 700 | 1 | |a McQuilten, Zoe |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Nichol, Alistair D |e verfasserin |4 aut | |
| 700 | 1 | |a Owen, David R J |e verfasserin |4 aut | |
| 700 | 1 | |a Parke, Rachael L |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Jane C |e verfasserin |4 aut | |
| 700 | 1 | |a Pollock, Katrina M |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Luis Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Marlene S |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Christina T |e verfasserin |4 aut | |
| 700 | 1 | |a Seymour, Christopher W |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar-Hari, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Turgeon, Alexis F |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Anne M |e verfasserin |4 aut | |
| 700 | 1 | |a Zarychanski, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a Lewis, Roger J |e verfasserin |4 aut | |
| 700 | 1 | |a Angus, Derek C |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a McArthur, Colin J |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Steve A |e verfasserin |4 aut | |
| 700 | 1 | |a Florescu, Simin |e investigator |4 oth | |
| 700 | 1 | |a Stanciu, Delia |e investigator |4 oth | |
| 700 | 1 | |a Zaharia, Mihaela |e investigator |4 oth | |
| 700 | 1 | |a Kosa, Alma |e investigator |4 oth | |
| 700 | 1 | |a Codreanu, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Fareed, Komal |e investigator |4 oth | |
| 700 | 1 | |a Kidwai, Aneela |e investigator |4 oth | |
| 700 | 1 | |a Kaye, Callum |e investigator |4 oth | |
| 700 | 1 | |a Coutts, Amanda |e investigator |4 oth | |
| 700 | 1 | |a MacKay, Lynn |e investigator |4 oth | |
| 700 | 1 | |a Summers, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Polgarova, Petra |e investigator |4 oth | |
| 700 | 1 | |a Farahi, Neda |e investigator |4 oth | |
| 700 | 1 | |a Fox, Eleonore |e investigator |4 oth | |
| 700 | 1 | |a Sapsford, David |e investigator |4 oth | |
| 700 | 1 | |a Bongaerts, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Featherstone, Peter |e investigator |4 oth | |
| 700 | 1 | |a Ng, Anthony |e investigator |4 oth | |
| 700 | 1 | |a McWilliam, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Hawcutt, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Rad, Laura |e investigator |4 oth | |
| 700 | 1 | |a O'Malley, Laura |e investigator |4 oth | |
| 700 | 1 | |a Whitbread, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Jones, Dawn |e investigator |4 oth | |
| 700 | 1 | |a Dore, Rachael |e investigator |4 oth | |
| 700 | 1 | |a Saunderson, Paula |e investigator |4 oth | |
| 700 | 1 | |a Kelsall, Olivia |e investigator |4 oth | |
| 700 | 1 | |a Cowley, Nicholas |e investigator |4 oth | |
| 700 | 1 | |a Wild, Laura |e investigator |4 oth | |
| 700 | 1 | |a Thrush, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Wood, Hannah |e investigator |4 oth | |
| 700 | 1 | |a Austin, Karen |e investigator |4 oth | |
| 700 | 1 | |a Donnelly, Adrian |e investigator |4 oth | |
| 700 | 1 | |a Kelly, Martin |e investigator |4 oth | |
| 700 | 1 | |a Smyth, Naoise |e investigator |4 oth | |
| 700 | 1 | |a O'Kane, Sinéad |e investigator |4 oth | |
| 700 | 1 | |a McClintock, Declan |e investigator |4 oth | |
| 700 | 1 | |a Warnock, Majella |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Ryan |e investigator |4 oth | |
| 700 | 1 | |a McCallion, Edmund |e investigator |4 oth | |
| 700 | 1 | |a Azaiz, Amine |e investigator |4 oth | |
| 700 | 1 | |a Charron, Cyril |e investigator |4 oth | |
| 700 | 1 | |a Godement, Mathieu |e investigator |4 oth | |
| 700 | 1 | |a Geri, Guillaume |e investigator |4 oth | |
| 700 | 1 | |a Vieillard-Baron, Antoine |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Paul |e investigator |4 oth | |
| 700 | 1 | |a McKenna, Shirley |e investigator |4 oth | |
| 700 | 1 | |a Hanley, Joanne |e investigator |4 oth | |
| 700 | 1 | |a Currie, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Allen, Barbara |e investigator |4 oth | |
| 700 | 1 | |a McGoldrick, Clare |e investigator |4 oth | |
| 700 | 1 | |a McMaster, Moyra |e investigator |4 oth | |
| 700 | 1 | |a Mani, Ashwin |e investigator |4 oth | |
| 700 | 1 | |a Mathew, Meghena |e investigator |4 oth | |
| 700 | 1 | |a Kandeepan, Revathi |e investigator |4 oth | |
| 700 | 1 | |a Vignesh, C |e investigator |4 oth | |
| 700 | 1 | |a Tv, Bharath |e investigator |4 oth | |
| 700 | 1 | |a Ramakrishnan, N |e investigator |4 oth | |
| 700 | 1 | |a James, Augustian |e investigator |4 oth | |
| 700 | 1 | |a Elvira, Evangeline |e investigator |4 oth | |
| 700 | 1 | |a Jayakumar, Devachandran |e investigator |4 oth | |
| 700 | 1 | |a Pratheema, Ramachandran |e investigator |4 oth | |
| 700 | 1 | |a Babu, Suresh |e investigator |4 oth | |
| 700 | 1 | |a Ebenezer, R |e investigator |4 oth | |
| 700 | 1 | |a Krishnamoorthy, S |e investigator |4 oth | |
| 700 | 1 | |a Ranganathan, Lakshmi |e investigator |4 oth | |
| 700 | 1 | |a Ganesan, Manisha |e investigator |4 oth | |
| 700 | 1 | |a Shree, Madhu |e investigator |4 oth | |
| 700 | 1 | |a Piva, Simone |e investigator |4 oth | |
| 700 | 1 | |a Focà, Emanuele |e investigator |4 oth | |
| 700 | 1 | |a Rizzoni, Damiano |e investigator |4 oth | |
| 700 | 1 | |a Boari, Gianluca |e investigator |4 oth | |
| 700 | 1 | |a Marchesi, Mattia |e investigator |4 oth | |
| 700 | 1 | |a Butler, Magdalena |e investigator |4 oth | |
| 700 | 1 | |a Cowdrey, Keri-Anne |e investigator |4 oth | |
| 700 | 1 | |a Mason, Brittany |e investigator |4 oth | |
| 700 | 1 | |a Woolett, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Duffy, Eamon |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yan |e investigator |4 oth | |
| 700 | 1 | |a Nakamuro, Hiromi |e investigator |4 oth | |
| 700 | 1 | |a Simmonds, Catherine |e investigator |4 oth | |
| 700 | 1 | |a McConnochie, Rachael |e investigator |4 oth | |
| 700 | 1 | |a O'Connor, Caroline |e investigator |4 oth | |
| 700 | 1 | |a West, Lauren |e investigator |4 oth | |
| 700 | 1 | |a El-Khawas, Khaled |e investigator |4 oth | |
| 700 | 1 | |a Richardson, Angus |e investigator |4 oth | |
| 700 | 1 | |a Hill, Dianne |e investigator |4 oth | |
| 700 | 1 | |a Commons, Robert |e investigator |4 oth | |
| 700 | 1 | |a Abdelkharim, Hussam |e investigator |4 oth | |
| 700 | 1 | |a Saxena, Manoj |e investigator |4 oth | |
| 700 | 1 | |a Muteithia, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Dobell-Brown, Kelsey |e investigator |4 oth | |
| 700 | 1 | |a Jha, Rajeev |e investigator |4 oth | |
| 700 | 1 | |a Kalogirou, Michael |e investigator |4 oth | |
| 700 | 1 | |a Ellis, Christine |e investigator |4 oth | |
| 700 | 1 | |a Krishnamurthy, Vinodh |e investigator |4 oth | |
| 700 | 1 | |a O'Connor, Aibhilin |e investigator |4 oth | |
| 700 | 1 | |a Thurairatnam, Saranya |e investigator |4 oth | |
| 700 | 1 | |a Mukherjee, Dipak |e investigator |4 oth | |
| 700 | 1 | |a Kaliappan, Agilan |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA |d 1948 |g 329(2023), 14 vom: 11. Apr., Seite 1183-1196 |w (DE-627)NLM000006939 |x 1538-3598 |7 nnns |
| 773 | 1 | 8 | |g volume:329 |g year:2023 |g number:14 |g day:11 |g month:04 |g pages:1183-1196 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2023.4480 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 329 |j 2023 |e 14 |b 11 |c 04 |h 1183-1196 | ||